Discovery of Pancreatic Ductal Adenocarcinoma-Related Aberrant Glycosylations: A Multilateral Approach of Lectin Microarray-Based Tissue Glycomic Profiling With Public Transcriptomic Datasets.

ABO blood group antigen Genotype-Tissue Expression (GTEx) The Cancer Genome Atlas (TCGA) basigin/CD147 glycosylation glycosyltransferase lectin microarray multi-omics

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 11 11 2019
accepted: 26 02 2020
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 2 4 2020
Statut: epublish

Résumé

Aberrant protein glycosylation is one of the most notable features in cancerous tissues, and thereby glycoproteins with disease-relevant glycosylation alterations are fascinating targets for the development of biomarkers and therapeutic agents. For this purpose, a reliable strategy is needed for the analysis of glycosylation alterations occurring on specific glycoproteins during the progression of cancer. Here, we propose a bilateral approach combining lectin microarray-based tissue glycomic profiling and database-derived transcriptomic datasets. First, lectin microarray was used to perform differential glycomic profiling of crude extracts derived from non-tumor and tumor regions of frozen tissue sections from pancreatic ductal adenocarcinoma (PDAC). This analysis revealed two notable tissue glycome alterations in PDAC samples: increases in sialylated glycans and bisecting

Identifiants

pubmed: 32232009
doi: 10.3389/fonc.2020.00338
pmc: PMC7082313
doi:

Types de publication

Journal Article

Langues

eng

Pagination

338

Informations de copyright

Copyright © 2020 Wagatsuma, Nagai-Okatani, Matsuda, Masugi, Imaoka, Yamazaki, Sakamoto and Kuno.

Références

Biochem Biophys Res Commun. 2008 May 30;370(2):259-63
pubmed: 18375199
Anal Chem. 2017 Jan 3;89(1):389-413
pubmed: 28105826
Oncotarget. 2016 Jun 7;7(23):35478-89
pubmed: 27007155
Annu Rev Pathol. 2015;10:473-510
pubmed: 25621663
Int J Mol Sci. 2014 Apr 15;15(4):6356-77
pubmed: 24739808
J Proteome Res. 2018 Dec 7;17(12):4097-4112
pubmed: 30359034
Nat Methods. 2005 Nov;2(11):851-6
pubmed: 16278656
Mol Biosyst. 2014 Feb;10(2):201-5
pubmed: 24301485
Mol Cancer Ther. 2018 Jan;17(1):183-195
pubmed: 28939555
Pancreas. 2014 Jan;43(1):109-17
pubmed: 23921962
Sci Rep. 2013;3:1065
pubmed: 23323209
Eur J Cancer. 2010 Dec;46(18):3345-50
pubmed: 20833034
Eur J Biochem. 1978 Apr;85(1):249-54
pubmed: 639818
Hepatology. 2010 Jul;52(1):174-82
pubmed: 20578261
Lab Invest. 2017 Sep;97(9):1103-1113
pubmed: 28581490
Pathol Oncol Res. 2016 Jul;22(3):443-7
pubmed: 26685886
Sci Rep. 2016 Nov 21;6:35210
pubmed: 27869218
Biochim Biophys Acta. 2016 Aug;1860(8):1596-607
pubmed: 26748235
Oncol Rep. 2014 Sep;32(3):1156-62
pubmed: 24970053
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Cancer Med. 2019 Jul;8(7):3511-3519
pubmed: 31070303
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3140-9
pubmed: 20971884
J Biol Chem. 2011 Jun 10;286(23):20345-53
pubmed: 21471226
Cancer Sci. 2019 Jul;110(7):2273-2283
pubmed: 31069878
Oncotarget. 2017 Jan 31;8(5):7691-7709
pubmed: 28032597
Mol Cell Proteomics. 2009 Jan;8(1):99-108
pubmed: 18697734
Nat Med. 2012 Jan 15;18(2):315-21
pubmed: 22245781
Front Oncol. 2019 Jul 10;9:636
pubmed: 31355147
PLoS One. 2015 Jun 15;10(6):e0130197
pubmed: 26075384
Int J Mol Sci. 2019 Feb 06;20(3):
pubmed: 30736315
Chembiochem. 2005 Jun;6(6):985-9
pubmed: 15798991
J Biol Chem. 2018 Apr 13;293(15):5659-5667
pubmed: 29475939
Arthritis Res Ther. 2016 May 21;18(1):112
pubmed: 27209430
Curr Protoc Chem Biol. 2013;5(1):1-23
pubmed: 23788322
Biochim Biophys Acta. 2014 Jan;1840(1):65-70
pubmed: 23999089
FEBS J. 2010 Jan;277(1):95-105
pubmed: 19919546
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Mol Cell Proteomics. 2019 Oct;18(10):2044-2057
pubmed: 31375533
Gastric Cancer. 2016 Apr;19(2):531-542
pubmed: 25840959
Glycoconj J. 1998 Oct;15(10):1033-7
pubmed: 10211708
Onco Targets Ther. 2014 Jan 16;7:117-34
pubmed: 24470763
Sci Rep. 2016 Feb 02;6:20297
pubmed: 26831207
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Lab Invest. 2019 Nov;99(11):1749-1765
pubmed: 31253865
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
J Biol Chem. 2002 Nov 29;277(48):45719-28
pubmed: 12235148
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Sci Rep. 2017 Mar 06;7:43560
pubmed: 28262709
APMIS. 2000 Jan;108(1):1-28
pubmed: 10698081
Drug Discov Today. 2018 May;23(5):1126-1138
pubmed: 29501708
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3
pubmed: 12149519
Oncol Lett. 2019 Aug;18(2):983-989
pubmed: 31423157
Chem Soc Rev. 2013 May 21;42(10):4443-58
pubmed: 23443201
Glycobiology. 2011 Aug;21(8):1060-70
pubmed: 21507904
Biomolecules. 2016 Apr 28;6(2):
pubmed: 27136596

Auteurs

Takanori Wagatsuma (T)

Project for Utilizing Glycans in the Development of Innovative Drug Discovery Technologies, Japan Bioindustry Association (JBA), Tokyo, Japan.
Center for Integrated Medical Research, Keio University School of Medicine, Tokyo, Japan.
Glycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan.

Chiaki Nagai-Okatani (C)

Glycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan.

Atsushi Matsuda (A)

Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan.

Yohei Masugi (Y)

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Masako Imaoka (M)

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Ken Yamazaki (K)

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Michiie Sakamoto (M)

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Atsushi Kuno (A)

Glycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan.

Classifications MeSH